CareDx, Inc.

CDNA09 Dec 2024
Healthcare
$25.48
+0.02 (+1.96%)
Lowest Today
$25.48
Highest Today
$25.53
Today’s Open
$25.48
Prev. Close
$25.04
52 Week High
$34.84
52 Week Low
$7.42
To Invest in CareDx, Inc.

CareDx, Inc.

Healthcare
CDNA09 Dec 2024
+0.02 (+1.96%)
1M
3M
6M
1Y
5Y
Low
$25.48
Day’s Range
High
$25.53
25.48
52 Week Low
$7.42
52-Week Range
52 Week High
$34.84
7.42
1 Day
-
1 Week
-2.41%
1 month return
+5.87%
3 month return
-8.57%
6 month return
+67.84%
1 Year return
+155.71%
3 Years return
-45.35%
5 Years return
+17.76%
10 Years return
-
Institutional Holdings
BlackRock Inc
9.86
Vanguard Group Inc
8.46
Bellevue Healthcare Ord
6.03
Bellevue Group AG
5.86
ARK Investment Management LLC
5.57
ARK Genomic Revolution
5.53
ARK Genomic Revolution ETF
4.83

Market Status

Fundamentals
Market Cap
1342.99 mln
PB Ratio
4.92
PE Ratio
0
Enterprise Value
1132.1 mln
Total Assets
466.83 mln
Volume

Company Financials

Fund house & investment objective

Company Information
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Organisation
CareDx, Inc.
Employees
635
Industry
Diagnostics & Research
CEO
Mr. John Walter Hanna Jr.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities